drugset
Drugs / GSK2132231A
last change Nov 2017 re-read 9 days ago

GSK2132231A

also known as MAGE-A3 cancer immunotherapeutic · MAGE-A3 immunotherapeutic
Developed for
melanoma
Investigated by
GlaxoSmithKline

Trials 4

today NCT00942162 · Ph 2 NCT00849875 · Ph 2 NCT00896480 · Ph 2 NCT00796445 · Ph 3
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 23 trials
Phase 2 NCT00942162 Aug 2009 → Jun 2012 melanoma GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00849875 May 2009 → Nov 2014 melanoma GlaxoSmithKline Terminated No outcome recorded
Phase 2 NCT00896480 May 2009 → Nov 2014 melanoma GlaxoSmithKline Completed No outcome recorded
Phase 31 trial · 1 missed
Phase 3 NCT00796445 Dec 2008 → Jan 2016 melanoma GlaxoSmithKline Terminated Missed primary

News releases announcing trial results or a regulatory action · 5

DateIssuerRelease
2014-04-02 GlaxoSmithKline Results Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer gsk.com ↗
However, the pre-planned independent third-party analysis of a proportion of the datav (to identify a gene signature classifier) has concluded that assessment of the third co-primary endpoint is not feasible due to an insufficient treatment effect.
2014-03-20 GlaxoSmithKline Results Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial gsk.com ↗
2014-03-20 Agenus Inc. Results GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-small Cell Lung Cancer Misses First Co-primary Endpoints agenusbio.com ↗
2013-09-05 GlaxoSmithKline Results The investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoint in Phase III melanoma clinical trial gsk.com ↗
2013-09-05 Agenus Inc. Results GSK’S MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint agenusbio.com ↗

All press releases naming this drug 5 releases

DateIssuerRelease

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as GSK2132231A ClinicalTrials.gov intervention name — accepted as the source's own label NCT00942162 ↗
3

NCT00796445 ↗

NCT00849875 ↗

NCT00896480 ↗
Known as MAGE-A3 cancer immunotherapeutic “Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine” PMID 29177094 ↗ Nov 2017
Known as MAGE-A3 immunotherapeutic “recombinant MAGE-A3 antigen combined with AS15 immunostimulant (MAGE-A3 immunotherapeutic)” PMID 29177094 ↗ Nov 2017
Route Intramuscular “Study products were administered as intramuscular (IM) injections” NCT00796445 ↗